Skip to main content

Table 2 Rate of patients with preoperative elevated tumor marker CA19-9.

From: Tumor markers as a diagnostic key for hilar cholangiocarcinoma

Variable Group a
(CA19-9 ≤ 1000 U/ml)
Group B
(CA19-9 > 1000 U/ml)
p-value
N = 111 25  
CA19-9 (U/ml) 208 ± 247 3864 ± 2999 0.00002
(Mean/±)    
CA19-9 (U/ml) 119 (0.3-1000) 2960 (1009-13500)  
(Median/range)    
Mean survival 23 ± 25 12 ± 22 > 0.05
(Months/±)    
Median survival 13 (3 to 38) 8 (1 to 9)  
(Months/IQR)    
Nonresectable 27 (30%) 16 (64%) 0.0006
  1. Mean and median survival of patients with CA19-9 serum levels ≤ 1000 U/ml (Group A) vs. > 1000 U/ml (Group B) in months. Rate of nonresectable tumor masses in Group A and Group B.
  2. (Data are means ± standard deviations, median and range or IQR respectively, p-value established by wilcoxon-test)